New drug aims to ease breathing and boost survival in heart shock
NCT ID NCT07583446
First seen May 14, 2026 · Last updated May 15, 2026 · Updated 1 time
Summary
This study tests if the drug istaroxime can help people with mild to moderate cardiogenic shock caused by acute heart failure. About 600 adults will receive either istaroxime or a placebo through an IV for 48 hours. Researchers will check if it improves breathing, blood pressure, and reduces the risk of death or further heart problems.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CARDIOGENIC SHOCK are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.